在射血分数降低的心力衰竭且心力衰竭恶化事件在出院前的老年住院患者中，是否应该起始维立西呱的治疗？
Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?
机构信息
Hospital Pharmacy, UZ Leuven, Leuven, Flemish Brabant, Belgium.
Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Flemish Brabant, Belgium.
出版信息
Eur J Hosp Pharm. 2023 Nov;30(6):367-369. doi: 10.1136/ejhpharm-2022-003305. Epub 2022 May 19.
Abstract
Heart failure (HF) occurs predominantly in older adults. HF patients have an increased risk for an acute exacerbation, which commonly requires hospitalisation. Such a worsening HF (WHF) event has an impact on prognosis. Vericiguat is a novel agent which has been shown to reduce the HF hospitalisation risk in patients with a recent WHF event. It is not fully clear how to position this novel agent in geriatric HF inpatients.
摘要
心力衰竭（HF）主要发生在老年人中。HF 患者急性加重的风险增加，通常需要住院治疗。这种恶化的 HF（WHF）事件对预后有影响。维立西呱是一种新型药物，已被证明可降低近期 WHF 事件患者的 HF 住院风险。目前尚不完全清楚如何在老年 HF 住院患者中定位这种新型药物。
相似文献
1
Should vericiguat be initiated in geriatric inpatients with heart failure with reduced ejection fraction and a worsening heart failure event prior to discharge?在射血分数降低的心力衰竭且心力衰竭恶化事件在出院前的老年住院患者中，是否应该起始维立西呱的治疗？
Eur J Hosp Pharm. 2023 Nov;30(6):367-369. doi: 10.1136/ejhpharm-2022-003305. Epub 2022 May 19.
2
Epidemiology of Worsening Heart Failure in a Population-based Cohort from Alberta, Canada: Evaluating Eligibility for Treatment With Vericiguat.加拿大艾伯塔省基于人群队列的心力衰竭恶化的流行病学：评估用维立西呱治疗的资格。
J Card Fail. 2022 Aug;28(8):1298-1308. doi: 10.1016/j.cardfail.2022.04.015. Epub 2022 May 16.
3
Vericiguat for the Treatment of Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event: A Cost-Effectiveness Analysis from the Perspective of Chinese Healthcare Providers.维立西呱用于治疗射血分数降低的心力衰竭恶化事件后的心力衰竭：中国医疗服务提供者视角的成本效益分析
Clin Drug Investig. 2023 Apr;43(4):241-250. doi: 10.1007/s40261-023-01253-y. Epub 2023 Mar 16.
4
Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event.威立西呱用于治疗射血分数降低的慢性心力衰竭恶化事件后的预算影响分析。
Adv Ther. 2021 May;38(5):2631-2643. doi: 10.1007/s12325-021-01681-2. Epub 2021 Apr 16.
5
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States.维立西呱在因心力衰竭住院的美国患者中的适用性。
JACC Heart Fail. 2023 Feb;11(2):211-223. doi: 10.1016/j.jchf.2022.11.007.
6
Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial.心力衰竭事件严重程度的分类：来自 VICTORIA 试验的见解。
J Card Fail. 2023 Aug;29(8):1113-1120. doi: 10.1016/j.cardfail.2023.04.015. Epub 2023 Jun 17.
7
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial.近期心力衰竭事件恶化患者使用非奈利酮：FINEARTS-HF试验
J Am Coll Cardiol. 2025 Jan 21;85(2):106-116. doi: 10.1016/j.jacc.2024.09.004. Epub 2024 Sep 29.
8
[New Treatment Strategies in Patients with Heart Failure with Reduced Ejection Fraction: Beyond Neurohormonal Inhibition].射血分数降低的心力衰竭患者的新治疗策略：超越神经激素抑制
G Ital Nefrol. 2024 Apr 29;41(2):2024-vol2.
9
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.心力衰竭和射血分数降低患者的反复住院治疗和维立西呱的反应。
JACC Heart Fail. 2024 May;12(5):839-846. doi: 10.1016/j.jchf.2023.12.005. Epub 2024 Feb 14.
10
Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.基于 SOLOIST-WHF 试验纳入标准，真实世界心力衰竭人群中索格列净的资格：来自瑞典心力衰竭注册登记处的数据。
Eur Heart J Cardiovasc Pharmacother. 2023 Jun 2;9(4):343-352. doi: 10.1093/ehjcvp/pvad012.
本文引用的文献
1
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
2
Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.根据索引心力衰竭事件评估维立西呱的临床结局和反应：来自 VICTORIA 试验的观察。
JAMA Cardiol. 2021 Jun 1;6(6):706-712. doi: 10.1001/jamacardio.2020.6455.
3
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.维立西呱的安全性、药效学和药代动力学特征：来自六项健康受试者 I 期研究的结果。
Eur J Clin Pharmacol. 2021 Apr;77(4):527-537. doi: 10.1007/s00228-020-03023-7. Epub 2020 Oct 30.
4
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.氨基末端 B 型利钠肽前体与临床结局：维立西呱治疗射血分数降低的心力衰竭研究。
JACC Heart Fail. 2020 Nov;8(11):931-939. doi: 10.1016/j.jchf.2020.08.008. Epub 2020 Oct 7.
5
Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.维立西呱的药效动力学和药代动力学相互作用特征：来自三项健康志愿者随机 I 期研究的结果。
Clin Pharmacokinet. 2021 Mar;60(3):337-351. doi: 10.1007/s40262-020-00935-6.
6
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.维立西呱治疗射血分数降低的心力衰竭患者的疗效。
N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
7
Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association.《心脏病与卒中统计-2020 更新：来自美国心脏协会的报告》。
Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
8
Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.射血分数降低的心力衰竭恶化患者的临床病程。
J Am Coll Cardiol. 2019 Mar 5;73(8):935-944. doi: 10.1016/j.jacc.2018.11.049.
9
Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association.执行摘要：《2016年心脏病和中风统计数据更新：美国心脏协会报告》
Circulation. 2016 Jan 26;133(4):447-54. doi: 10.1161/CIR.0000000000000366.
10
Soluble guanylate cyclase: a potential therapeutic target for heart failure.可溶性鸟苷酸环化酶：心力衰竭的潜在治疗靶点。
Heart Fail Rev. 2013 Mar;18(2):123-34. doi: 10.1007/s10741-012-9323-1.
Zotero 插件